Baird analyst Colleen Kusy raised the firm’s price target on Oculis (OCS) to $41 from $37 and keeps an Outperform rating on the shares. The firm updated it model following Q4 results which showed programs for DME, AON, and Dry Eye are progressing.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis price target raised to $32 from $31 at BofA
- Oculis price target lowered to $29 from $30 at H.C. Wainwright
- Oculis Holding AG Faces Heightened Cybersecurity Risks Amid Geopolitical Tensions
- Oculis Holding AG Reports 2024 Financial Results
- Oculis Holding’s Promising Ophthalmology Portfolio and Financial Stability Lead to Buy Rating